We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
RNS Number : 9329J
Diurnal Group PLC
29 April 2022
29 April 2022
Diurnal Group plc
("Diurnal" or the "Company")
Total Voting Rights
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that pursuant to its block admission facility, details of which were announced on 13 December 2021, it has recently issued 383,002 ordinary shares of GBP0.05 each in the Company ("Ordinary Shares") in satisfaction of the exercise of options. The new Ordinary Shares rank pari passu with the Company's existing shares.
In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as of 29 April 2022, the Company has 169,719,533 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 169,719,533.
The above figure of 169,719,533 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Richard Bungay, Interim Chief Executive Officer Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886 and Joint Corporate Broker) 2500 Corporate Finance: Freddy Crossley, Emma Earl Corporate Broking: Rupert Dearden Stifel Nicolaus Europe Limited (Joint Corporate +44 (0) 20 7710 Broker) 7600 Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea, William Palmer-Brown Corporate Broking: Nick Adams, Nick Harland +44 (0)20 3727 FTI Consulting (Media and Investor Relations) 1000 Simon Conway Victoria Foster Mitchell Alex Davis
Notes to Editors
About Diurnal Group plc
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TVRBSGDSLXDDGDC
(END) Dow Jones Newswires
April 29, 2022 10:37 ET (14:37 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions